Abstract 486P
Background
Our research group has previously established the cost-effectiveness (CE) of lung cancer screening (LCS) with low-dose computed tomography (LDCT) for both high-risk smokers and non-smokers in Hong Kong (HK). Integrating LCS into the existing infrastructure in HK however requires systematic and rigorous design and execution. Thus, we undertook sensitivity and scenario analyses for LCS beyond fundamental base-case examination. The aim was to explore balance between clinical efficacy and resource optimization for LCS implementation in HK.
Methods
A CE analysis was conducted using decision tree and state-transition Markov model to simulate identification, diagnosis, and treatments for a high-risk population defined by the NELSON study and the TALENT study. One-way sensitivity analysis (OSA) was conducted with ±20% variation of the base-case parameter values. Scenario analyses were undertaken to explore the CE of LCS with varying costs. The incremental cost-effectiveness (ICER) was estimated as costs per quality-adjusted life-year (QALY).
Results
OSA showed that LDCT costs were the main driver for the ICER of LCS targeting heavy smokers, 20% increase in LDCT costs led to an ICER of USD 18,002 (22% higher than base-case ICER). Meanwhile, 20% increase in the treatments costs for stage I LC led to an ICER of 10,844 (7% higher than base-case ICER) for the LCS targeting high-risk non-smokers. Scenario analyses additionally indicated that restraining costs for CT scan, diagnosis, and early-stage LC treatments would yield a reduction in ICER (Table). Table: 486P
Scenario analysis | Smoker | Non smokers | ||
ICER (USD) ∗ | Reduction in ICER ∗ | ICER (USD) | Reduction in ICER | |
Base-case analysis | $14,723 | NA. | $10,096 | NA. |
Cut down unit costs for low-dose CT scans (LDCT) - USD $ 191 | $12,070 | 18% | $9,520 | 6% |
Cut down unit costs for LDCT - USD $ 127 | $9,377 | 36% | $8,934 | 12% |
Cut down unit costs for LDCT - USD $ 64 | $6,684 | 55% | $8,349 | 17% |
Half diagnostic costs for stage I - USD $ 836 (per person) | $14,472 | 2% | $9,635 | 5% |
Half diagnostic costs for stage IV - USD $ 3,922 (per person) | $14,969 | -2% | $8,872 | 12% |
Half treatment costs for the ongoing phase for stage I patients (per 3 months) - USD $ 247 | $13,296 | 10% | $8,777 | 13% |
Half treatment costs for the ongoing phase for stage IV patients (per 3 months) - USD $ 417 | $14,974 | -2% | $10,145 | 0% |
Conclusions
Fiscal restraint on CT scanning and early-stage LC treatments expenditures are necessary to ensure feasible and sustainable LCS implementation in HK. Our findings provide important benchmarks for the HK Government’s consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca Hong Kong.
Disclosure
H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. X. Pan: Financial Interests, Personal, Financially compensated role: i-DNA. All other authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract